Boult Wade Tennant
UPC » The UPC: 2020 and beyond

As 2019 drew to a close, a statement was issued by the Chairman of the UPC Preparatory Committee, Alexander Ramsay.  As well as touching on progress made regarding the UPC case management system and recruitment campaign, the statement refers to an interview given by Mr Ramsay in which he provided his forecast for the UPC into 2020 and beyond.

Currently, the introduction of the UPC is being delayed by both a pending case at the German Constitutional Court, and uncertainties introduced by Brexit.  In his interview, Mr Ramsay indicated that he is eagerly awaiting the German judgement, which is expected to occur in the first quarter of 2020.  Assuming that the German judgement enables Germany to ratify the UPC agreement, Mr Ramsay stated that they would need at least 8 months after Germany has ratified in order to allow for the provisional application phase of the UPC.  Only after the provisional application phase would the UPC become operational.

With regard to Brexit, Mr Ramsay commented that there is a strong political will to try to keep the UK as part of the UPC, and he believes that the UK will indeed be part of the UPC when it becomes operational.  Mr Ramsay further indicated that we might realistically expect the UPC to be operational in early 2021.  Nonetheless, these comments were made just prior to the results of the UK General Election, and it is now highly likely that the UK will leave the EU on 31 January 2020.  Previously, the UK ratified the UPC Agreement, indicating an intention to be part of the Unified Patent Court and Unitary Patent system when it comes into force. However, signatories to the UPC Agreement are required to be EU member states, so it is currently unclear how the UK’s participation in the Unified Patent Court will be achieved after Brexit without requiring revisions to the UPC Agreement.  Therefore, in light of an imminent Brexit, we believe that there are likely to be significant delays in terms of implementation of the UPC.

Relevant sectors
Food and beverage
  • Nutrition
  • Retail
  • Beverages
Artificial intelligence and machine learning
Consumer goods and retail
  • Anti-counterfeit devices
  • Moda
  • Health, fitness and sport
  • Beauty
  • Fashion
  • Luxury goods
  • Retail
  • Household goods
Trade marks
  • Mechanical products
  • Services
  • Telecommunications
  • Financial services
  • Cosmetics and perfumery
  • Consumer goods
Chemicals
  • Agrochemicals
  • Catalysts
  • Dispersions and colloids
  • Lubricants
  • Polymers and plastics
Materials
  • Advanced materials
  • Composite materials
  • Metallurgy and alloys
  • Nanotechnology
Industrial manufacturing and processing
  • Packaging
  • Polymers and plastics
  • Printing tech
  • Additive manufacturing
  • Coatings
  • Construction
Electronics and electrical devices
  • Restaurants and bars
  • Travel and leisure
  • Testing systems, control systems, signal processing
  • Computer and IT architecture and system design
  • Medical devices
  • Optics
  • Robotics
  • Scientific instruments
  • Semiconductor devices
  • Wearable tech and human interfaces
Communications and networks
  • Oceanography, marine
  • Cloud computing
  • Internet of things (IOT)
  • Wired and wireless networks
Energy and green technologies
  • Solar power
  • Wind turbines
  • Water, oil and gas, nuclear, fusion, fission
  • Clean air
  • Fuel cells and battery technology
  • Renewables and recycling
  • Biofuels
Automotive
  • Autonomous vehicles
  • Electric vehicles
  • Engines
Aerospace
  • Commercial aviation
  • Defence and security
  • Space and satellites
  • Unmanned aerial vehicles
Pharmaceuticals
  • Pharmaceuticalsceutical formulations
  • Diagnostics
  • Drug delivery
  • Generic market entry
  • Medicinal chemistry
  • Methods of production and synthesis
  • Personalised medicine/disease biomarkers
  • Pharmaceutical formulations
  • Polymorphs
  • Small molecule pharmaceuticals
  • Supplementary protection certificates (SPCs)
Biotechnology
  • Bioinformatics
  • Next generation sequencing
  • Women’s health products
  • Vaccinology (e.g. viral vectors; mRNA vaccines)
  • Therapeutic antibodies
  • Synthetic biology
  • Stem cell therapies
  • Recombinant protein production and purification
  • Personalised medicine/disease biomarkers
  • Nucleic acid synthesis
  • Supplementary protection certificates (SPCs)
  • Immuno-oncology (e.g. checkpoint inhibitors; modified T cells)
  • GM crops
  • Genomic and molecular tools and methods
  • Gene editing (e.g. CRISPR)
  • Drug delivery
  • Biosimilars
  • Antibody manufacture and formulation
  • Antibody engineering
Medical devices and diagnostics 
  • Immuno-oncology
  • Artificial intelligence
  • Devices
  • Diagnostic instruments
  • Digital health
  • Drug delivery
  • In vitro diagnostics
  • Medtech
Computing and software
  • Digital assistants, virtual assistants and software agents
  • Multimedia, audio/video processing and animation
  • Metaverse, virtual reality (VR) and augmented reality (AR)
  • Data management and storage, databases and data compression
  • Data and software security, cryptography and digital rights management (DRM)
  • Software applications and systems, mobile applications, user interfaces
  • Natural language processing
  • Search engines
  • Robotic process automation
  • Quantum computing
  • Motor capture
  • Machine vision
  • Fintech and adtech
  • Computer games
  • Communications and networks
  • Blockchain and distributed ledgers
  • Bioinformatics
  • Signal processing
  • Artificial intelligence and machine learning